Edition:
India

Celsion Corp (CLSN.OQ)

CLSN.OQ on NASDAQ Stock Exchange Capital Market

1.71USD
18 Oct 2019
Change (% chg)

$0.02 (+1.18%)
Prev Close
$1.69
Open
$1.70
Day's High
$1.75
Day's Low
$1.69
Volume
8,026
Avg. Vol
15,139
52-wk High
$2.70
52-wk Low
$1.36

Latest Key Developments (Source: Significant Developments)

Celsion Says Q2 Loss Per Share $0.29
Thursday, 15 Aug 2019 

Aug 14 (Reuters) - Celsion Corp ::ORATION REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q2 LOSS PER SHARE $0.29.Q2 EARNINGS PER SHARE ESTIMATE $-0.32 -- REFINITIV IBES DATA.ENDED Q2 OF 2019 WITH $21.8 MILLION IN CASH, INVESTMENT SECURITIES AND INTEREST RECEIVABLE.  Full Article

Celsion Corp Reports Q1 Loss Per Share $0.12
Wednesday, 15 May 2019 

May 15 (Reuters) - Celsion Corp ::ORATION REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q1 LOSS PER SHARE $0.12.CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND INTEREST RECEIVABLE AT MARCH 31, 2019 WAS $23.8 MILLION.  Full Article

Celsion Corp Reports Q3 Loss Per Share Of $0.26
Thursday, 15 Nov 2018 

Nov 14 (Reuters) - Celsion Corp ::ORATION REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q3 LOSS PER SHARE $0.26.EXPECTS TO RECEIVE APPROXIMATELY $10 MILLION FROM SALE OF ITS NEW JERSEY STATE NOLS IN Q4 OF 2018.SALE OF ITS NEW JERSEY STATE NOLS IS EXPECTED TO CONTRIBUTE TO FUNDING OPERATIONS INTO Q4 OF 2020.  Full Article

Celsion Announces FDA Clearance Of The OVATION II Study For The Evaluation Of GEN-1 Immunotherapy
Thursday, 4 Jan 2018 

Jan 4 (Reuters) - Celsion Corp ::CELSION ANNOUNCES FDA CLEARANCE OF THE OVATION II STUDY FOR THE EVALUATION OF GEN-1 IMMUNOTHERAPY TO TREAT NEWLY DIAGNOSED STAGE III/IV OVARIAN CANCER.CELSION CORP - EXPECTS TO INITIATE ENROLLMENT OF PHASE I PORTION OF OVATION II STUDY IN FIRST HALF OF 2018.CELSION CORP - COMPANY EXPECTS TO HAVE 25% OF OVATION II STUDY ENROLLED BY END OF 2018.  Full Article

Celsion reports Q3 loss of $0.70/shr
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Celsion Corp :Celsion Corporation reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.70.  Full Article